Evidence map›Paper›PMID 35530568›Full record

ArticleArab journal of urology2022

Creation and validation of the harmonized Arabic version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP).

Mohannad A Awad, Luke Hallgarth, Ghassan A Barayan, Mohammed Shahait, Ramiz Abu-Hijlih, Ala'a Farkouh, Raed A Azhar, Musab M Alghamdi, Ahmad Bugis, Said Yaiesh and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arab journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mohannad A AwadDepartment of Surgery, Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.ORCID https://orcid.org/0000-0002-2483-9527
Luke HallgarthDepartment of Surgery, Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.
Ghassan A BarayanDepartment of Surgery, Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.
Mohammed ShahaitDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Ramiz Abu-HijlihDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Ala'a FarkouhDepartment of Surgery, King Hussein Cancer Center, Amman, Jordan.
Raed A AzharDepartment of Surgery, Division of Urology, King Abdulaziz University, Jeddah, Saudi Arabia.
Musab M AlghamdiDepartment of Surgery, Division of Urology, King Abdulaziz University, Jeddah, Saudi Arabia.
Ahmad BugisDepartment of Surgery, Division of Urology, King Abdulaziz University, Jeddah, Saudi Arabia.
Said YaieshUrology Unit, Department of Surgery, Mubarak Al-Kabeer Hospital, Kuwait, Kuwait.
Saad AldousariDepartment of Surgery (Urology Division), Faculty of Medicine, Kuwait University, Kuwait, Kuwait.
Alaeddin BarhamUrology, Surgical Subspecialties Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Mohamed SaedUrology, Surgical Subspecialties Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Ayman MoussaUrology, Surgical Subspecialties Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Waleed HassenUrology, Surgical Subspecialties Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Shelly NaudMedical Biostatistics, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Mark K PlanteDepartment of Surgery, Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.
Richard GrunertDepartment of Surgery, Division of Urology, University of Vermont Medical Center, Burlington, VT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Tocreate and validate a translated Arabic version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP), a validated patient-reported outcome (PRO) widely used for assessing the quality of life in patients with prostate cancer (PCa). Patients and Methods: Using the established protocol as defined by the Professional Society for the Health Economics and Outcomes Research (ISPOR) for translating patient care questionnaires, a harmonised translated Arabic version of EPIC-CP was created. The questionnaire was tested in native Arabic speakers from four different Arabic countries (Saudi Arabia, United Arab Emirates, Jordan, and Kuwait). Cronbach's alpha and interclass coefficient correlation (ICC) analyses were used to test the internal consistency and test-retest reliability, respectively. In addition, PCa characteristics were collected for participants. Results: In total, 168 patients with PCa participated in the study (39 from Saudi Arabia, 23 from United Arab Emirates, 65 from Jordan, and 41 from Kuwait). In all, 52 (31%) participants repeated the questionnaire for test-retest reliability analysis. The median (interquartile range [IQR]) age of patients included in the study was 66 (61-71) years. The median (IQR) PSA level was 9.8 (6-19) ng/mL. Most patients had Grade Group 2 PCa at diagnosis (31%), clinical stage cT1 (42%), managed primarily by urology (79%), and the primary treatment was radical prostatectomy (71%). The total Cronbach's alpha coefficient was 0.84 demonstrating an acceptable internal consistency. The total ICC was also acceptable at 0.64. Conclusion: The Arabic version of the EPIC-CP is a reliable and valid tool for assessing health-related quality of life for Arabic patients with PCa.

Indexed as

Prostate cancerquality of lifequestionnairetranslationvalidation

Identifiers

PMID35530568
PMCPMC9067989

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.